Navigation Links
Guardian Introduces New Program to Help Employers Control Health Care Premiums
Date:10/17/2007

Guardian Premium Protect Sets Single-Digit Medical Renewal Rates at Initial

Purchase

NEW YORK, Oct. 17 /PRNewswire/ -- The Guardian Life Insurance Company of America (Guardian), a leading provider of employee and voluntary benefits for small and midsize businesses, today announced the introduction of a new program that helps employers manage health care costs by locking in a single- digit medical premium renewal rate when companies sign-up.

Traditional plans have an annual renewal cycle and often require employers to estimate their future healthcare expenses. This annual cycle has proven difficult for some employers at a time when health care premiums have significantly outpaced inflation.

Guardian Premium Protect(SM), a new offering for groups with 51-150 employees was designed to mitigate this problem by eliminating the guesswork related to second year medical benefit renewals.

The program will be available in New Jersey, Maryland, Washington DC, Virginia and the Chicago and New York metro areas, for plans sold with effective dates beginning October 1.

"Guardian Premium Protect(SM) takes the guesswork out of health care budgeting," said Tim Bireley, Vice President, Group Medical, Guardian. "By locking in their second-year rates when they sign up, and incorporating additional member cost sharing, Guardian is providing employers with a path to a manageable, predictable healthcare budget. Employers enrolled in our program can save money and time on the budgeting process. Producers can help relieve their client's anxieties about unpredictable and out-of-control health plan renewal rates by offering the rate at the point of sale."

Guardian Premium Protect is a two-year medical PPO program with a prescription drug benefit, vision discount access*, wellness resources and high and low cost-sharing plans.

Added Bireley, "Medical is an important part of Guardian's overall portfolio of group be
'/>"/>

SOURCE The Guardian Life Insurance Company of America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. p53, the Guardian of Our Genome
2. E Merck introduces Livogen Z with zinc sulphate
3. TI Cycles Introduces Foldman
4. Canada Introduces Mandatory Nutrition Labeling
5. Amgen introduces Autoinjector For Treating Anemia
6. Cuba Introduces New Device for Detecting Vascular Diseases
7. China Introduces Solar-powered Baths
8. Allergan Introduces ‘Dermal Filler’ for Smile Lins
9. UAE Introduces Cervical Cancer Vaccine
10. Cynosure Introduces Higher Power Smartlipo(TM) LaserBodySculpting Workstation
11. Iceland Introduces Smoking Ban in Bars and Restaurants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...consumers on indoor air quality, ANN ARBOR, Mich....onth,according the Environmental Protection Agency...ng this opportunity to educate consumers on the,im...erious condition. The,EPA states that asthma sent ...n the year 2000, and according to the American Lun...
(Date:5/12/2008)...ors, there exists among the multitude of warrior c... patiently lying in wait to launch their attacks. ...leukemia initiating cells (LICs), these stealth po...apy and undaunted by targeted cancer therapies. Wh...of remission, it is the LICs that bear responsibil...
(Date:5/12/2008)...f-life care for older people in the final stages o...ublished in the May issue of Journal of Clinical N...ementia from suffering from protracted, potentiall...aper, Professor of Nursing for The Open University...a major international public health concern becaus...
(Date:5/12/2008)...Ruth Kluck at Melbournes Walter and Eliza Hall Ins...hanism by which cells destroy themselves. In this ...the cell to self-destruct by puncturing its power ... by the WEHI team. The discovery is an important s...s designed to regulate cell death. , Dr Kluck a...
Breaking Medicine News(10 mins):Health News:Asthma Awareness Month Spawns Healthy Advice 2Health News:Arsenic-based therapy shown to help eradicate leukemia-initiating cells 2Health News:Arsenic-based therapy shown to help eradicate leukemia-initiating cells 3Health News:End-stage dementia patients deserve the same access to palliative care as people with cancer 2Health News:End-stage dementia patients deserve the same access to palliative care as people with cancer 3Health News:Key step in the 'puncture' mechanism of cell death revealed 2
...31 states during the past year, an estimated two-t...tal diseases such as// diabetes, stroke and cancer...state government efforts to curb the overweight ep...rt from the Trust for America's Health. The repo...
...oie, offered to donate nearly 60% of his liver to ...parently did not have any// second thoughts about ...avoie, 54, had been suffering hepatitis C for almo...amaged his liver. There was no option left to reve...
...ealthcare problem, which has tickled the curiosity...es, is also the increasing// numbers of myths doin...rch on the subject of obesity has been conducted f...dy conducted in Britain has painted a dismal scena...
...lesbians and single women as heterosexual couples,....// This call was made by the British Fertility S... wide disparity" on the social criteria used for a...e of treatment. Their recommendations sent to the...
Other Medicine News:Health News:Rise in Obesity Rates in 31 States 2Health News:Rise in Obesity Rates in 31 States 3
(Date:5/12/2008)... All Patients in Cohort 3 Demonstrated Improvement...e Therapeutic Potential of HspE7, SAN DIEGO, May ...cals,Corporation (TSX: NVN) today announced positi... ongoing Phase 1 clinical trial of its lead produc...aepithelial neoplasia, or,CIN, a precursor to cerv...
(Date:5/9/2008)... TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Ma...side effects. These can include nausea and,vomitin...r, chronic use.,Such symptoms can lead patients to...tions to pain management for physicians. The novel...y acting oral analgesic, provided pain,relief for ...
(Date:5/9/2008)... Boosts Cytopia,s development of early pipeline ca... /- Cytopia Limited,(ASX: C...ti-cancer drug,discovery and development collabora...reement leverages Cytopia,s early stage drug disco...geted therapeutics that is one of the,fastest grow...
(Date:5/8/2008)... MIAMI, May 8 /- Globus Medical, Inc...acturer in the world and a recognized,leader in mo...completion of,enrollment in its SECURE(R)-C Cervic...ce is designed to mimic the normal motion of the s...on as an alternative to fusion in,the treatment of...
Breaking Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Genetics determine optimal drug dose of common anticoagulant 112 1Genetics determine optimal drug dose of common anticoagulant 112 2YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 1YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 2YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 3YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 4New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 1New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 2New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 3New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 4New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 5Consequences of online HIV denial 3B and more 120 1Consequences of online HIV denial 3B and more 120 2Consequences of online HIV denial 3B and more 120 3Consequences of online HIV denial 3B and more 120 4
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States.
Medicine Products: